Table 2 Pathological conditions associated with MCT1 and MCT4 expression
From: Tumor-stroma metabolic relationship based on lactate shuttle can sustain prostate cancer progression
Tissue | Expression/total number (%) | P-value# | ||
|---|---|---|---|---|
Null | Low* | High** | ||
MCT1 | ||||
BPH | 48% (29/60) | 47% (28/60) | 5% (3/60) | 0.07 |
PCa | 31% (25/80) | 56% (45/80) | 13% (10/80) | |
MCT4 | ||||
BPH | 92% (55/60) | 5% (3/60) | 3% (2/60) | <0.01 |
PCa | 35% (28/80) | 45% (36/80) | 20% (16/80) | |
Stromal MCT4 | ||||
BPH | 50% (30/60) | 45% (27/60) | 2% (3/60) | <0.01 |
PCa | 25% (20780) | 61% (49/80) | 14% (11/80) | |